Biotechnology FDA To Review Two Cell Therapies For Multiple Myeloma This Week – Johnson & Johnson And Bristol-Myers – Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study Read more
Biotechnology Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley – Arcellx (NASDAQ:ACLX) Read more
Stockmarkets Morgan Stanley bullish on Arcellx shares after myeloma data ‘promising’ By biedexmarkets.com Read more
Stockmarkets Legend Biotech’s CARVYKTI therapy for myeloma gets positive CHMP opinion By biedexmarkets.com Read more
Biotechnology FDA Approves Johnson & Johnson’s Reduced Tecvayli Dosing In Pretreated Multiple Myeloma Patients – Johnson & Johnson (NYSE:JNJ) Read more